Summary
Two hundred and twenty patients with nervous conditions in which obsessionality was a prominent underlying cause were treated with a new benzodiazepine compound, bromazepam. Patients had previously been treated using other benzodiazepine compounds with unsatisfactory results. The majority improved significantly and maintained their improvement while bromazepam was continued.